Vireo Growth (VREOF) Amortizatization of Intangibles (2020 - 2025)
Vireo Growth (VREOF) reported Amortizatization of Intangibles of $415285.0 for Q4 2025, up 690.33% on a YoY basis from $52546.0 in Q4 2024, and up 628.37% sequentially from $57016.0 in Q3 2025.
Vireo Growth (VREOF) Amortizatization of Intangibles (2020 - 2025) Analysis & Trends
Vireo Growth (VREOF) has 6 years of Amortizatization of Intangibles data on file, last reported at $415285.0 in Q4 2025.
- For the quarter ending Q4 2025, Amortizatization of Intangibles rose 690.33% year-over-year to $415285.0; the trailing twelve-month figure through Dec 2025 stood at $575677.0 (up 160.48% YoY), and the FY2025 full-year result was $575677.0, up 160.48% from the prior year.
- Amortizatization of Intangibles improved to $415285.0 in Q4 2025, from $57016.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.6 million in Q4 2021 to a low of $3376.0 in Q2 2025.
- A 5-year average of $385158.0 and a median of $154884.5 in 2021 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles jumped 5676.19% in 2021 and slumped 93.98% in 2025, its largest moves.
- Tracing VREOF's Amortizatization of Intangibles over 5 years: stood at $1.6 million in 2021, then sank by 64.7% to $572473.0 in 2022, then tumbled by 66.07% to $194262.0 in 2023, then sank by 72.95% to $52546.0 in 2024, then soared by 690.33% to $415285.0 in 2025.
- Business Quant data shows VREOF's Amortizatization of Intangibles at $415285.0 in Q4 2025, $57016.0 in Q3 2025, and $3376.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 415,285.00 |
| Dec 31, 2025 | 415,285.00 |
| Sep 30, 2025 | 57,016.00 |
| Sep 30, 2025 | 57,016.00 |
| Jun 30, 2025 | 3,376.00 |
| Jun 30, 2025 | 3,376.00 |
| Mar 31, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 52,546.00 |
| Dec 31, 2024 | 52,546.00 |
| Sep 30, 2024 | 59,562.00 |
| Sep 30, 2024 | 59,562.00 |
| Jun 30, 2024 | 56,087.00 |
| Jun 30, 2024 | 56,087.00 |
| Mar 31, 2024 | 52,815.00 |
| Mar 31, 2024 | 52,815.00 |
| Dec 31, 2023 | 194,262.00 |
| Dec 31, 2023 | 194,262.00 |
| Sep 30, 2023 | 207,329.00 |
| Sep 30, 2023 | 207,329.00 |